Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2007

01-02-2007

Is Routine Sentinel Lymph Node Biopsy Indicated in Women Undergoing Contralateral Prophylactic Mastectomy? Magee-Womens Hospital Experience

Authors: Atilla Soran, MD, MPH, FACS, Jeffrey Falk, MD, FACS, Marguerite Bonaventura, MD, Donald Keenan, MD, PhD, Gretchen Ahrendt, MD, FACS, Ronald Johnson, MD, FACS

Published in: Annals of Surgical Oncology | Issue 2/2007

Login to get access

Abstract

Introduction

The routine use of sentinel node biopsy (SLNB) at the time of prophylactic mastectomy remains controversial. This retrospective study was undertaken to determine if SLNB is justified in patients undergoing CPM.

Methods

Between 1999 and 2004, 155 patients underwent contralateral prophylactic mastectomy (CPM) at the Magee-Womens Hospital of University of Pittsburgh Medical Center. Eighty patients (51.6%) had SLNB performed at the time of CPM. The therapeutic mastectomy and the CPM specimens were evaluated for histopathology. Goldflam’s classification was used to determine the risk of malignancy in the CPM specimens.

Results

Pathology in the therapeutic mastectomy specimens included 105 (68%) invasive carcinomas and 50 (32%) in-situ carcinomas. Multicentricity and/or multifocality were reported in 49.7%, and 70% were estrogen receptor positive. Two invasive breast cancers and three cases of DCIS were diagnosed in 155 CPM specimens (n = 5, 3.2%). The median number of SLN identified was 2 (range 1–6) from the CPM axilla. Two patients had positive SLNB for metastatic carcinoma (n = 2/80, 2.5%) with no primary tumor identified in the prophylactic mastectomy specimen. In both patients the therapeutic mastectomy was for recurrent invasive carcinoma in patients with a prior history of axillary node dissection. Occult carcinoma was found in five prophylactic mastectomy specimens: two invasive and three DCIS. Only 1 out of the 75 patients not undergoing SLNB at the time of their initial surgery would have required axillary staging for a previously undiagnosed invasive cancer in the CPM specimen on final pathology. Of all 155 patients undergoing CPM, only 4 (2.5%) had identified final pathologic findings where axillary staging with SLNB was beneficial. There was no evidence of arm lymphedema in any patient who had undergone CPM and SLNB at a median follow-up of 24 months.

Conclusion

Although SLNB is a minimally invasive method of axillary staging, this retrospective study does not support its routine use in patients undergoing CPM.
Literature
1.
http://www.cancer.org/downloads/stt/CAFF06EsCsMc.pdf
2.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703–20PubMedCrossRef
3.
Peralta EA, Ellenhorn JD, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000; 180:439–45PubMedCrossRef
4.
Boughey, JC, Khakpour N, Meric-Bernstam F, et al. Routine use of sentinel lymph node surgery in prophylactic mastectomy is not warranted. Ann Surg Oncol (Suppl) 2006; 13:P64, page 53
5.
Dupont EL, Kuhn MA, McCann C, et al. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg 2000; 180:274–7PubMedCrossRef
6.
Cripe MH, Lehr A, Beran L, Liang W, Sickle-Santanello B. Incidence of occult contralateral breast cancer detected by magnetic resonance imaging. Ann Surg Oncol (Suppl) 2006; 13:26,P195, page 90
7.
Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004; 101:1977–86PubMedCrossRef
8.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676–89PubMedCrossRef
9.
Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401–8PubMedCrossRef
10.
Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Phillips KA. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clin Genet 2003; 64:111–21PubMedCrossRef
11.
Bilimoria M, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995; 45:263–78PubMedCrossRef
12.
Hartmann LC, Schnaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340:77–84PubMedCrossRef
13.
Kroll SS, Miller M, Schusterman M, et al. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction. Ann Surg Oncol 1994; 1:457–61PubMedCrossRef
14.
Barone JE, Tucker JB, Perez JM, Odom SR, Ghevariya V. Evidence-based medicine applied to sentinel lymph node biopsy in patients with breast cancer. Am Surg 2005; 71:66–70PubMed
15.
Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol. B-27.JCO 2005; 23:2694–702CrossRef
16.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055–62PubMedCrossRef
17.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159–64PubMedCrossRef
18.
Geiger AM, Yu O, Herrinton LJ, Barlow WE, Harris EL, Rolnick S, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med 2005; 165:516–20PubMedCrossRef
19.
Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003; 21:1675–81PubMedCrossRef
20.
Kern KA, Borgen P, Mamounas EP, McMasters KM, Singletary E. Contemporary surgery 2005; 6:63–72
21.
Lee JM, Dominguez F, Gadd M, et al. Detecting occult breast cancer in prophylactic mastectomies: sentinel node biopsy vs pre-operative MRI. Ann Surg Oncol 2006; (Suppl) 13–26, P26, page 9
22.
Sood A, Youssef IM, Heiba SI, et al. Alternative lymphatic pathway after previous axillary node dissection in recurrent/primary breast cancer.Clin Nucl Med 2004; 29:698–702PubMedCrossRef
23.
Newman EA, Cimmino VM, Sabel MS, et al. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol 2006; 13:52–7PubMedCrossRef
24.
Port ER, Fey J, Gemignani ML, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002; 195:167–72PubMedCrossRef
25.
Bass SS, Cox CE, Ku NN, Reintgen DS. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999; 189:183–94PubMedCrossRef
26.
Cody HS. Management of the axilla in early stage breast cancer: will sentinel node biopsy end the debate? J Surg Oncol 1999; 71:137–39PubMedCrossRef
27.
Cox CE, Bass SS, McCann CR, et al. Lymphatic mapping and sentinel node biopsy in patients with breast cancer. Annu Rev Med 2000; 51:525–42PubMedCrossRef
28.
Leidenius M, Leivonen M, Vironen J, von Smitten K. The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005; 92:23–31PubMedCrossRef
Metadata
Title
Is Routine Sentinel Lymph Node Biopsy Indicated in Women Undergoing Contralateral Prophylactic Mastectomy? Magee-Womens Hospital Experience
Authors
Atilla Soran, MD, MPH, FACS
Jeffrey Falk, MD, FACS
Marguerite Bonaventura, MD
Donald Keenan, MD, PhD
Gretchen Ahrendt, MD, FACS
Ronald Johnson, MD, FACS
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9264-9

Other articles of this Issue 2/2007

Annals of Surgical Oncology 2/2007 Go to the issue

OriginalPaper

Surgical Results of Early Gastric Cancer and Proposing a Treatment Strategy

OriginalPaper

Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

OriginalPaper

Prognostic Factors for Pulmonary Metastasectomy in Hepatocellular Carcinoma

OriginalPaper

Serum Albumin as a Significant Prognostic Factor for Patients with Gastric Carcinoma

OriginalPaper

Radioguided Parathyroidectomy in Patients with Familial Hyperparathyroidism

OriginalPaper

Personality Predicts Quality of Life Six Months after the Diagnosis and Treatment of Breast Disease